A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Serlopitant (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors Menlo Therapeutics
- 31 Oct 2019 According to a Menlo Therapeutics media release, the company expects to report top-line data from this trial in January or February of 2020.
- 15 Oct 2019 Planned End Date changed from 1 Apr 2020 to 1 Jan 2020.
- 15 Oct 2019 Planned primary completion date changed from 1 Apr 2020 to 1 Dec 2019.